_256_384.jpg)
News | January 24, 2026
Cipla reports consolidated PAT of Rs. 675.80 Cr
Cipla has reported total income of Rs. 7,280.82 crore during the period ended December 31, 2025
Cipla has reported total income of Rs. 7,280.82 crore during the period ended December 31, 2025
Laurus Labs has reported total income of Rs. 1,784.05 crore during the period ended December 31, 2025
Jagsonpal Pharmaceuticals has reported total income of Rs. 75.92 crore during the period ended December 31, 2025
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
Tatva Chintan Pharma Chem has reported total income of Rs. 133.06 crore during the period ended December 31, 2025
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
Subscribe To Our Newsletter & Stay Updated
